Literature DB >> 14583139

Evaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitis.

Kirk R Wilhelmus1.   

Abstract

Observational studies suggest that a pharmacodynamic index helps to predict the therapeutic outcome of respiratory and other infections. This study explored the prognostic importance of a ratio of the achievable corneal level for a fluoroquinolone to the fluoroquinolone's minimal inhibitory concentration (MIC) for corneal isolates of 391 patients with bacterial keratitis. The peak concentration and the area under the concentration curve (AUC) in the cornea were estimated from reported values achieved with topical ciprofloxacin. The inhibitory quotient (IQ) was calculated as the ratio of the estimated peak achievable corneal ciprofloxacin concentration to the ciprofloxacin MIC of keratitis isolates, and the area under the inhibitory curve (AUIC) was defined as the expected 24-hour AUC divided by the MIC. The probability of clinical improvement of ciprofloxacin-treated bacterial keratitis was 90% or more if ciprofloxacin's IQ was above 8 or the AUIC was greater than 151. A pharmacodynamic index relating corneal pharmacokinetic and susceptibility concentrations may correlate with the clinical response of bacterial keratitis to fluoroquinolone therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583139     DOI: 10.1089/108076803322473042

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  5 in total

1.  Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.

Authors:  Prajna Lalitha; Muthiah Srinivasan; P Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Vicky Cevallos; Catherine E Oldenburg; Kathryn J Ray; Christine M Toutain-Kidd; David V Glidden; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2012-03-23       Impact factor: 9.079

2.  Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.

Authors:  Gail Torkildsen; Joel W Proksch; Aron Shapiro; Stephanie K Lynch; Timothy L Comstock
Journal:  Clin Ophthalmol       Date:  2010-04-26

3.  Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.

Authors:  Kathryn J Ray; Lalitha Prajna; Muthiah Srinivasan; Manoharan Geetha; Rajarathinam Karpagam; David Glidden; Catherine E Oldenburg; Catherine Q Sun; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  JAMA Ophthalmol       Date:  2013-03       Impact factor: 7.389

4.  Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.

Authors:  Darlene Miller
Journal:  Clin Ophthalmol       Date:  2008-03

5.  Hospital-Associated Multidrug-Resistant MRSA Lineages Are Trophic to the Ocular Surface and Cause Severe Microbial Keratitis.

Authors:  Paulo J M Bispo; Lawson Ung; James Chodosh; Michael S Gilmore
Journal:  Front Public Health       Date:  2020-06-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.